Smoking cessation

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 165-176

  Rennard, Stephen I ^a   Daughton, David M ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cessation; Pharmacotherapy; Smoking; Treatment

Indexed keywords

CESSATION; PHARMACOTHERAPY; SMOKING; TREATMENT;

BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; HUMANS; NICOTINE; NICOTINIC AGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS;

EID: 84893431157     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.11.002     Document Type: Review

References (86)

1. King James I of England. A counterblaste to tobacco. 1604. Available at: Accessed September 2013. http://www.laits.utexas.edu/poltheory/james/blaste/.
2. US Department of Health, Education, and Welfare. Smoking and health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. 1964.
3. US Department of Health and Human Services The health benefits of smoking cessation. A report of the Surgeon General 1990, 90-8416. Department of Health and Human Services (US), Washington, DC, Publication No. (CDC).
4. Fiore M.C., Jaén C.R., Baker T.B., et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline 2008, US Department of Health and Human Services, Public Health Service.
5. Escobedo L.G., Anda R.F., Smith P.F., et al. Sociodemographic characteristics of cigarette smoking initiation in the United States. JAMA 1990, 264:1550-1555.
6. Pierce J.P., White V.M., Emery S.L. What public health strategies are needed to reduce smoking initiation?. Tob Control 2012, 21:258-264.
7. Headen S.W., Bauman K.E., Deane G.D., et al. Are the correlates of cigarette smoking initiation different for black and white adolescents?. Am J Public Health 1991, 81:854-858.
8. In: Preventing tobacco use among youth and young adults: a report of the Surgeon General. Atlanta (GA): 2012.
9. Johnston L.D., O'Malley P.M., Bachman J.G., et al. Monitoring the future national survey results on drug use, 1975-2012 2013, University of Michigan, Ann Arbor.
10. Gotti C., Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004, 74:363-396.
11. Drenan R.M., Lester H.A. Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations. Pharmacol Rev 2012, 64:869-879.
12. Gotti C., Clementi F., Fornari A., et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009, 78:703-711.
13. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 2010, 11:389-401.
14. Leslie F.M., Mojica C.Y., Reynaga D.D. Nicotinic receptors in addiction pathways. Mol pharmacol 2013, 83:753-758.
15. Slotkin T.A., Ryde I.T., Seidler F.J. Additive and synergistic effects of fetal nicotine and dexamethasone exposure on cholinergic synaptic function in adolescence and adulthood: implications for the adverse consequences of maternal smoking and pharmacotherapy of preterm delivery. Brain Res Bull 2010, 81:552-560.
16. Goriounova N.A., Mansvelder H.D. Short- and long-term consequences of nicotine exposure during adolescence for prefrontal cortex neuronal network function. Cold Spring Harb Perspect Med 2012, 2:a012120.
17. Shiffman S. Tobacco "chippers"-individual differences in tobacco dependence. Psychopharmacology 1989, 97:539-547.
18. Shiffman S., Paty J.A., Gnys M., et al. Nicotine withdrawal in chippers and regular smokers: subjective and cognitive effects. Health Psychol 1995, 14:301-309.
19. Benowitz N.L., Jacob P. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. JPharmacol Exp Ther 1990, 254:1000-1005.
20. Benowitz N.L., Jacob P., Kozlowski L.T., et al. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. NEngl J Med 1986, 315:1310-1313.
21. Olausson P., Jentsch J.D., Taylor J.R. Repeated nicotine exposure enhances reward-related learning inthe rat. Neuropsychopharmacology 2003, 28:1264-1271.
22. Henningfield J.E., London E.D., Benowitz N.L. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 1990, 263:2049-2050.
23. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57:79-115.
24. Heatherton T.F., Kozlowski L.T., Frecker R.C., et al. The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991, 86:1119-1127.
25. Centers for Disease Control and Prevention (CDC) Cigarette smoking among adults and trends in smoking cessation-United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:1227-1232.
26. Fiore M.C., Bailey W.C., Cohen S.J. Smoking cessation. Guideline technical report no. 18 1997, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville (MD), Publication no. AHCPR 97-Noo4.
27. Fiore M., Bailey W., Cohen S., et al. Treating tobacco use and dependence 2000, US Department Of Health and Human Services, Rockville (MD).
28. Daughton D.M., Susman J., Sitorius M., et al. Transdermal nicotine therapy and primary care: importance of counseling, demographic and patient selection factors on one-year quit rates. Arch Fam Med 1998, 7:425-430.
29. Gwaltney C.J., Metrik J., Kahler C.W., et al. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav 2009, 23:56-66.
30. Gulliver S.B., Hughes J.R., Solomon L.J., et al. An investigation of self-efficacy, partner support and daily stresses as predictors of relapse to smoking in self-quitters. Addiction 1995, 90:767-772.
31. Cromwell J., Bartosch W.J., Fiore M.C., et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 1997, 278(21):1759-1766.
32. Cinciripini P.M., Wetter D.W., McClure J.B. Scheduled reduced smoking: effects on smoking abstinence and potential mechanisms of action. Addict Behav 1997, 22:759-767.
33. Hughes J.R., Solomon L.J., Livingston A.E., et al. Arandomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. Drug Alcohol Depend 2010, 111:105-113.
34. Lindson-Hawley N., Aveyard P., Hughes J.R. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2012, (11). CD008033.
35. Anthonisen N.R., Connett J.E., Kiley J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 1994, 272:1497-1505.
36. Tashkin D., Kanner R., Bailey W., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001, 357:1571-1575.
37. Tashkin D.P., Rennard S., Hays J.T., et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011, 139:591-599.
38. Rigotti N.A., Clair C., Munafo M.R., et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2012, (5). CD001837.
39. Stead L.F., Perera R., Lancaster T. Asystematic review of interventions for smokers who contact quitlines. Tob Control 2007, 16(Suppl 1):i3-i8.
40. Rennard SI, Rigotti NA, Daughton DM. Pharmacotherapy for smoking cessation in adults. In: UpToDate. 2013.
41. Jorenby D.E., Leischow S.J., Nides M.A., et al. Acontrolled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NEngl J Med 1999, 340:685-691.
42. Allen S.S., Hatsukami D.K., Christianson D. Nicotine withdrawal and depressive symptomatology during short-term smoking abstinence: a comparison of postmenopausal women using and not using hormone replacement therapy. Nicotine Tob Res 2003, 5:49-59.
43. Hajek P., West R., Foulds J., et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999, 159:2033-2038.
44. Rigotti N.A. Clinical practice. Treatment of tobacco use and dependence. NEngl J Med 2002, 346:506-512.
45. Killen J.D., Fortmann S.P., Newman B., et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. JConsult Clin Psychol 1990, 58:85-92.
46. Dautzenberg B., Nides M., Kienzler J.L., et al. Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC Clin Pharmacol 2007, 7:11.
47. Smith S.S., McCarthy D.E., Japuntich S.J., et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009, 169:2148-2155.
48. Pickworth W.B., Bunker E.B., Henningfield J.E. Transfermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berl) 1994, 115:9-14.
49. Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch Intern Med 1994, 154:989-995.
50. Mahmarian J.J., Moye L.A., Nasser G.A. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. JAm Coll Cardiol 1997, 30:125-130.
51. Joseph A.M., Norma S.M., Ferry L.H. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. NEngl J Med 1996, 335:1792-1798.
52. Bohadana A., Nilsson F., Rasmussen T., et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000, 160:3128-3134.
53. Schneider N.G., Cortner C., Gould J.L., et al. Comparison of craving and withdrawal among four combination nicotine treatments. Hum Psychopharmacol 2008, 23:513-517.
54. Piper M.E., Smith S.S., Schlam T.R., et al. Arandomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009, 66:1253-1262.
55. Hughes J.R., Stead L.F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007, (1). CD000031.
56. Hurt R.D., Sachs D.P., Glover E.D., et al. Acomparison of sustained-release bupropion and placebo for smoking cessation. NEngl J Med 1997, 337:1195-1202.
57. Swan G.E., McAfee T., Curry S.J., et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003, 163:2337-2344.
58. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior 2009, FDA Drug Safety Newsletter.
59. Coe J.W., Brooks P.R., Vetelino M.G., et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. JMed Chem 2005, 48:3474-3477.
60. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55.
61. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63.
62. Tonstad S., Tonnesen P., Hajek P., et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296:64-71.
63. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012, (4). CD006103.
64. Hughes J.R., Russ C.I., Arteaga C.E., et al. Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a cross-study analysis. Addict Behav 2011, 36:1288-1291.
65. Rennard S., Hughes J., Cinciripini P.M., et al. Arandomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012, 14:343-350.
66. Oncken C., Gonzales D., Nides M., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006, 166:1571-1577.
67. Gunnell D., Irvine D., Wise L., et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009, 339:b3805.
68. Singh S., Loke Y.K., Spangler J.G., et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011, 183:1359-1366.
69. Prochaska J.J., Hilton J.F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012, 344:e2856.
70. FDA. FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. Accessed April 1, 2013. http://www.fda.gov/drugs/drugsafety/ucm330367.htm.
71. Moore TJ, Cohen MR, Furberg CD. Strong safety signal seen for new varenicline risks In: Institute for Safe Medicine Practices; 2008. Accessed April 1, 2013. http://www.ismp.org/docs/vareniclinestudy.asp.
72. FDA. Available at: 2008. Accessed April 1, 2013. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ccm077547.htm.
73. Stead L.F., Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012, (10). CD008286.
74. Gourlay S.G., Stead L.F., Benowitz N.L. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004, (3). CD000058.
75. Higuchi L.M., Khalili H., Chan A.T., et al. Aprospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol 2012, 107:1399-1406.
76. Broekema M., ten Hacken N.H., Volbeda F., et al. Airway epithelial changes in smokers but not in ex-smokers with asthma. Am J Respir Crit Care Med 2009, 180:1170-1178.
77. Polosa R., Thomson N.C. Smoking and asthma: dangerous liaisons. Eur Respir J 2013, 41:716-726.
78. Buist A.S., Sexton G.J., Nagy J.M., et al. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976, 114:115-122.
79. Swan G.E., Hodgkin J.E., Roby T., et al. Reversibility of airways injury over a 12-month period following smoking cessation. Chest 1992, 101:607-612.
80. Borgerding M., Klus H. Analysis of complex mixtures-cigarette smoke. Exp Toxicol Pathol 2005, 57(Suppl 1):43-73.
81. Stratton K., Shetty P., Wallace R., et al. Clearing. Clearing the smoke: assessing the science base for tobacco harm reduction 2001, National Academy Press, Washington, DC.
82. Rodu B. The scientific foundation for tobacco harm reduction, 2006-2011. Harm Reduct J 2011, 8:19.
83. Hansson J., Galanti M.R., Hergens M.P., et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol 2012, 27:771-779.
84. Nordenvall C., Nilsson P.J., Ye W., et al. Tobacco use and cancer survival: a cohort study of 40,230 Swedish male construction workers with incident cancer. Int J Cancer 2013, 132:155-161.
85. Arefalk G., Hergens M.P., Ingelsson E., et al. Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts. Eur J Prev Cardiol 2012, 19:1120-1127.
86. Lee P.N. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 2011, 59:197-214.